1. Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. 2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. 3. Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
✉ Corresponding authors: Zhongyang Wang, Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China, E-mail: wangzhy6sysu.edu.cn, Tel: +86-13802500048. Xiangling Yang, Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510655, China, E-mail: yangxl28sysu.edu.cn, Tel: +86-13527630320.More
Citation:
Su Y, Huang Q, Lu L, Qu H, Wang D, Qiu J, Li W, Lin M, Liu H, Wang Z, Yang X. Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer. J Cancer 2022; 13(2):706-714. doi:10.7150/jca.65214. https://www.jcancer.org/v13p0706.htm
Neuronal pentraxin 2 (NPTX2), a secretory protein of neuronal pentraxins, was first identified in the nervous system. Several studies have shown that expression levels of NPTX2 are associated with the development of various cancers. However, whether NPTX2 is involved in prostate cancer progression is unclear. Herein, we found that NPTX2 is significantly reduced in prostate cancer tissues and cancer cell lines compared to control prostate tissues and control prostatic epithelial cell lines. Furthermore, the NPTX2 promoter is highly methylated in prostate cancer cells. Consistently, NPTX2 could be restored by treatment with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (decitabine, 5-AZA-dC). Overexpression of NPTX2 inhibited prostate cancer cell proliferation both in vitro and in vivo. In conclusion, our study demonstrated that NPTX2 acts as a tumor suppressor gene in prostate cancer.
Keywords: cancer targeted therapy, DNA methylation, demethylation, NPTX2, prostate cancer
Citation styles
APA
Su, Y., Huang, Q., Lu, L., Qu, H., Wang, D., Qiu, J., Li, W., Lin, M., Liu, H., Wang, Z., Yang, X. (2022). Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer. Journal of Cancer, 13(2), 706-714. https://doi.org/10.7150/jca.65214.
ACS
Su, Y.; Huang, Q.; Lu, L.; Qu, H.; Wang, D.; Qiu, J.; Li, W.; Lin, M.; Liu, H.; Wang, Z.; Yang, X. Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer. J. Cancer 2022, 13 (2), 706-714. DOI: 10.7150/jca.65214.
NLM
Su Y, Huang Q, Lu L, Qu H, Wang D, Qiu J, Li W, Lin M, Liu H, Wang Z, Yang X. Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer. J Cancer 2022; 13(2):706-714. doi:10.7150/jca.65214. https://www.jcancer.org/v13p0706.htm
CSE
Su Y, Huang Q, Lu L, Qu H, Wang D, Qiu J, Li W, Lin M, Liu H, Wang Z, Yang X. 2022. Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer. J Cancer. 13(2):706-714.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.